348 related articles for article (PubMed ID: 34986246)
21. Antifungal Therapies for Aspergillus spp.: Present and Future.
Eschenauer GA
Semin Respir Crit Care Med; 2024 Feb; 45(1):61-68. PubMed ID: 38151025
[TBL] [Abstract][Full Text] [Related]
22. [Emerging azole antifungals].
Wolff M; Bouadma L; Mourvillier B
Therapie; 2006; 61(3):227-33. PubMed ID: 16989123
[TBL] [Abstract][Full Text] [Related]
23. Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections.
Neoh CF; Chen SC; Lanternier F; Tio SY; Halliday CL; Kidd SE; Kong DCM; Meyer W; Hoenigl M; Slavin MA
Clin Microbiol Rev; 2024 Jun; 37(2):e0000423. PubMed ID: 38551323
[TBL] [Abstract][Full Text] [Related]
24. [Innovative therapies for treatment of invasive fungal diseases].
Mellinghoff SC; Cornely OA; Mammadova P; Sprute R; Stemler J
Dtsch Med Wochenschr; 2024 May; 149(10):560-568. PubMed ID: 38657595
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?
Bassetti M; Vena A; Bouza E; Peghin M; Muñoz P; Righi E; Pea F; Lackner M; Lass-Flörl C
Clin Microbiol Infect; 2020 Aug; 26(8):1024-1033. PubMed ID: 32120042
[TBL] [Abstract][Full Text] [Related]
26. Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections.
Shaw KJ; Ibrahim AS
J Fungi (Basel); 2020 Oct; 6(4):. PubMed ID: 33105672
[TBL] [Abstract][Full Text] [Related]
27. Advances in anti-fungal therapies.
Waterer G
Mycopathologia; 2021 Oct; 186(5):665-672. PubMed ID: 34268702
[TBL] [Abstract][Full Text] [Related]
28. Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix.
August BA; Kale-Pradhan PB
Pharmacotherapy; 2024 Jun; 44(6):467-479. PubMed ID: 38721866
[TBL] [Abstract][Full Text] [Related]
29. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.
Wiederhold NP; Locke JB; Daruwala P; Bartizal K
J Antimicrob Chemother; 2018 Nov; 73(11):3063-3067. PubMed ID: 30032217
[TBL] [Abstract][Full Text] [Related]
30. Recent Antifungal Pipeline Developments against
Treviño-Rangel RJ; González GM; Montoya AM; Rojas OC; Elizondo-Zertuche M; Álvarez-Villalobos NA
J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354911
[TBL] [Abstract][Full Text] [Related]
31. CYP51 Paralogue Structure Is Associated with Intrinsic Azole Resistance in Fungi.
Van Rhijn N; Bromley M; Richardson M; Bowyer P
mBio; 2021 Oct; 12(5):e0194521. PubMed ID: 34607450
[TBL] [Abstract][Full Text] [Related]
32. New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species.
Silva LN; de Mello TP; de Souza Ramos L; Branquinha MH; Dos Santos ALS
Curr Top Med Chem; 2019; 19(28):2527-2553. PubMed ID: 31654512
[TBL] [Abstract][Full Text] [Related]
33. Case Commentary: Long-Term Fosmanogepix Use in a Transplant Recipient with Disseminated Aspergillosis Caused by Azole-Resistant Aspergillus calidoustus.
Kline A; Lionakis MS
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0236821. PubMed ID: 35072513
[TBL] [Abstract][Full Text] [Related]
34. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments.
Gintjee TJ; Donnelley MA; Thompson GR
J Fungi (Basel); 2020 Feb; 6(1):. PubMed ID: 32106450
[TBL] [Abstract][Full Text] [Related]
35. Non-Aspergillus Hyaline Molds: Emerging Causes of Sino-Pulmonary Fungal Infections and Other Invasive Mycoses.
Jacobs SE; Wengenack NL; Walsh TJ
Semin Respir Crit Care Med; 2020 Feb; 41(1):115-130. PubMed ID: 32000288
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.
Wiederhold NP
J Fungi (Basel); 2022 Aug; 8(8):. PubMed ID: 36012845
[TBL] [Abstract][Full Text] [Related]
37. Antifungal resistance in superficial mycoses.
Gupta AK; Venkataraman M
J Dermatolog Treat; 2022 Jun; 33(4):1888-1895. PubMed ID: 34132155
[TBL] [Abstract][Full Text] [Related]
38. Emerging Issues in Antifungal Resistance.
Perfect JR; Ghannoum M
Infect Dis Clin North Am; 2020 Dec; 34(4):921-943. PubMed ID: 33131575
[TBL] [Abstract][Full Text] [Related]
39. Novel Antifungals and
Vahedi-Shahandashti R; Houbraken J; Birch M; Lass-Flörl C
J Fungi (Basel); 2023 Jun; 9(6):. PubMed ID: 37367585
[TBL] [Abstract][Full Text] [Related]
40. Emergence of the Molds Other than Aspergillus in Immunocompromised Patients.
Arif S; Perfect JR
Clin Chest Med; 2017 Sep; 38(3):555-573. PubMed ID: 28797495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
